HES-1 Antibody - BSA Free

Western Blot: HES-1 Antibody [NBP1-30912] - PC-12 whole cell extract.12 % SDS-PAGE HES1 antibody [N1], N-term dilution: 1:1000

Immunoprecipitation: HES-1 Antibody [NBP1-30912] - A431 whole cell lysate/extract A : Control with 2.5 ug of pre-immune rabbit IgG B : Immunoprecipitation of HES1 by 2.5 ug of HES1 antibody 12% SDS-PAGE The immunoprecipitated HES1 protein was detected by HES1 antibody diluted at 1 : 1000. EasyBlot anti-rabbit IgG (HRP) was used as a secondary reagent.

Western Blot: HES-1 Antibody [NBP1-30912] - Various whole cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with HES1 antibody [N1], N-term diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.

HES-1 antibody [N1], N-term detects HES-1 protein at nucleus by immunofluorescent analysis.Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: HES-1 protein stained by HES-1 antibody [N1], N-term (NBP1-30912) diluted at 1:2000.Red: alpha Tubulin, a cytoskeleton marker, stained by alpha Tubulin antibody [GT114] diluted at 1:1000.Blue: Hoechst 33342 staining.

MCF-7 whole cell and nuclear extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with HES-1 antibody [N1], N-term (NBP1-30912) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Interleukin-33 (IL-33) decreases bone marrow-derived monocytes (BMMs) osteoclastogenesis by inhibiting Notch1 activity. (A) Western blot analysis of Notch1 and Hes-1 expression in osteoclast progenitors incubated with CM-CRE in the presence of miR-34a-5p antagomir. (B–D) Quantification of Notch1, Jag1, and Hes-1 expression in osteoclast progenitors incubated with CM-CRE in the presence of miR-34a-5p antagomir. (E) Western blot analysis of Notch1 and Hes-1 expression in osteoclast progenitors induced by IL-33 in the presence of miR-34a-5p antagomir. (F–H) Quantification of Notch1, Jag1, and Hes-1 expression in osteoclast progenitors treated with IL-33 in the presence of miR-34a-5p antagomir. (I–K) BMMs osteoclastic formation and tartrate-resistant acid phosphatase (TRAP) activity assay after treatment with 20 ng/ml IL-33 in the presence of Jag-1. Red arrows indicated multinucleated osteoclasts. Scale bars represent 100 um. (L–O) Quantification of Trap, Cathepsin K, Nfatc1, and C-fos expression in osteoclast progenitors treated with 20 ng/ml IL-33 in the presence of Jag-1. *P < 0.05, **P < 0.01, ***P < 0.001. P values were analyzed by one-way ANOVA. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29085370), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Interleukin-33 (IL-33) decreases bone marrow-derived monocytes (BMMs) osteoclastogenesis by inhibiting Notch1 activity. (A) Western blot analysis of Notch1 and Hes-1 expression in osteoclast progenitors incubated with CM-CRE in the presence of miR-34a-5p antagomir. (B–D) Quantification of Notch1, Jag1, and Hes-1 expression in osteoclast progenitors incubated with CM-CRE in the presence of miR-34a-5p antagomir. (E) Western blot analysis of Notch1 and Hes-1 expression in osteoclast progenitors induced by IL-33 in the presence of miR-34a-5p antagomir. (F–H) Quantification of Notch1, Jag1, and Hes-1 expression in osteoclast progenitors treated with IL-33 in the presence of miR-34a-5p antagomir. (I–K) BMMs osteoclastic formation and tartrate-resistant acid phosphatase (TRAP) activity assay after treatment with 20 ng/ml IL-33 in the presence of Jag-1. Red arrows indicated multinucleated osteoclasts. Scale bars represent 100 um. (L–O) Quantification of Trap, Cathepsin K, Nfatc1, and C-fos expression in osteoclast progenitors treated with 20 ng/ml IL-33 in the presence of Jag-1. *P < 0.05, **P < 0.01, ***P < 0.001. P values were analyzed by one-way ANOVA. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29085370), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu, Mu, Rt, Po, Bv
• Applications: WB, ICC/IF, IP
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free

HES-1 Antibody - BSA Free Summary

• Immunogen: Carrier-protein conjugated synthetic peptide encompassing a sequence within the N-terminus region of human HES-1. The exact sequence is proprietary.
• Localization: Nucleus
• Predicted Species: Porcine (100%), Bovine (100%). Backed by our 100% Guarantee.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: HES1
• Purity: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:100-1:2000
  • Immunoprecipitation 1:100-1:500
  • Western Blot 1:500-1:3000
• Theoretical MW: 30 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS, 20% Glycerol
• Preservative: 0.025% Proclin 300
• Purity: Antigen Affinity-purified

Alternate Names for HES-1 Antibody - BSA Free

• BHLHB39
• bHLHb39hairy homolog (Drosophila)
• Class B basic helix-loop-helix protein 39
• FLJ20408
• Hairy and enhancer of split 1
• hairy and enhancer of split 1, (Drosophila)
• Hairy homolog
• Hairy-like protein
• HES1
• HES-1
• hHL
• HL
• HRY
• HRYHHL
• transcription factor HES-1

Background

Hes1 is a transcriptional repressor of genes that require a bHLH protein for their transcription. It may act as a negative regulator of myogenesis by inhibiting the functions of MYOD1 and ASH1. Hes1 is expressed in developing neuroectodermal and endodermal endocrine tissues, and Hes1 deficient embryos show severe defects in neuronal development, as well as pancreatic hypoplasia.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

&#9888; WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause reproductive toxicity with developmental effects.  For more information go to www.P65Warnings.ca.gov.

Publications for HES-1 Antibody (NBP1-30912)(1)

Publication using NBP1-30912

• Kang H, Yang K, Xiao L et al. Osteoblast Hypoxia-Inducible Factor-1a Pathway Activation Restrains Osteoclastogenesis via the Interleukin-33-MicroRNA-34a-Notch1 Pathway. Front Immunol. 2017-10-31 [PMID: 29085370] (WB, Mouse)

Bioinformatics

• Gene Symbol: HES1